Send to

Choose Destination
Oncoimmunology. 2012 Jul 1;1(4):544-546.

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection.

Author information

Department of Immunology; Memorial Sloan-Kettering Cancer Center; Howard Hughes Medical Institute; New York, NY USA.


We report that cryoablation of primary tumors synergizes with anti-CTLA-4 treatment to mediate rejection of secondary tumors in the TRAMP mouse model of prostate cancer. T cells, in particular CD8(+) T cells specific for the TRAMP antigen SPAS-1, were enriched in both secondary tumors and spleens of combination-treated mice.

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center